Study of Rhizoxin in Head and Neck Cancer
Author Information
Author(s): J Verweij, J Wanders, Th Gil, P Schoffski, G Catimel, A te Velde, PHM de Mulder
Primary Institution: Rotterdam Cancer Institute
Hypothesis
To test the anti-tumour activity of rhizoxin in recurrent and/or metastatic squamous cell head and neck cancer.
Conclusion
Rhizoxin has minor activity in recurrent and/or metastatic squamous cell head and neck cancer.
Supporting Evidence
- Two objective partial responses were observed, lasting 7.5 and 3.5 months.
- Overall response rate regarding evaluable patients is 8%.
- Severe pain at the tumour site was a notable side effect.
Takeaway
This study looked at a new drug called rhizoxin to see if it helps people with a type of throat cancer, but it didn't work very well.
Methodology
Patients with recurrent or metastatic squamous cell head and neck cancer were treated with rhizoxin and monitored for response and toxicity.
Limitations
The study had a small sample size and only two partial responses were observed.
Participant Demographics
30 males and 2 females, median age 60 (range 31-75).
Statistical Information
Confidence Interval
95% confidence interval 1-26%.
Want to read the original?
Access the complete publication on the publisher's website